



**Narayana Translational Research Centre (NTRC)**

**Conducted the workshop on**

**Good Clinical Practice**

**Tuesday, January 5, 2021; 4 pm to 6 pm**

***Via zoom online portal***

## Speaker



**SD Rajendran, M. Pharm., Ph.D.,  
Director and Head-Operations,  
Scitus Pharma Services Private Limited,  
Chennai – 600124, Tamil Nadu, India.**

## Patron



**Dr. Surya Prakasa Rao, MD  
Professor and Dean  
Narayana Medical College**

## Convenor



**Dr. Sivakumar Vijayaraghavalu, Ph.D.  
Professor and Head,  
Narayana Translational Research Centre**

The convenor commenced the session with good afternoon greetings to all the participants. He invited all of them with an immense pleasure on behalf of Narayana Medical College and the honorable dean Dr. Surya Prakasa Rao to the workshop *on “Good Clinical Practice - GCP”* by an eminent speaker – Dr. SD Rajendran.

He then continued to introduce the speaker as follows – Dr. SD Rajendran is currently managing director for Scitus Pharma, a private limited that he

established in 2017. He also served in academia as the professor and head for the department of pharmacy practice for 25 years (1983-2008) in JSS college of pharmacy, Ooty (Queen of Hills), Tamil Nadu (TN), India. Many of the leading academic pharmacy professional or industrial pharmacist both in India or abroad are students of Professor Dr. SD Rajendran.

In addition to his academic experience; he also has industrial work experience.

He headed the medical affairs team for 5 years in a Hyderabad based company

named - Sristek Clinical Research Solution Limited. Then he moved to Par Biosciences private limited and served as a senior director for clinical operations for 3 years.

His long CV short -

Dr. Rajendran, served as core team member in drafting the guidelines of “**National Pharmacovigilance Program**” of Ministry of Health, Government of India and also served as a peripheral center coordinator from 2002-2008.

He authored and reviewed more than 150 regulatory submission documents for phase trials and he conducted more than 220 bioequivalence studies spanning various therapeutic areas.

#### Education:

He did his bachelors from highly reputed Madras Medical College (MMC), Chennai, TN and then Master's degree from JSS Ooty. He also obtained PG diploma in

clinical pharmacy, from the society of hospital pharmacist of Australia, Melbourne. He did a training fellowship – “The Weary Dunlop fellowship” in clinical pharmacy practice at Repatriation General Hospital, Adelaide, Australia. He got PhD in pharmaceutical Sciences from well known - Kakatiya University, Telangana.

He has good knowledge about Clinical Pharmacy Practice, Clinical Pharmacokinetics including population pharmacokinetics, as mentioned earlier

he has conducted BA/BE studies, all types of phase trials. He also did PK/PD evaluation in clinical practice. He is well versed with ICH-GCP guidelines, regulatory requirements for clinical studies, pharmacotherapeutics and also in quality management systems. The convenor told that with more than 4 decades – 40 years of experience in the clinical research field. We felt, that he will be the appropriate speaker for this workshop. Convenor humbly requested Dr. Rajendran, Managing Director of Scitus Pharma to take over the session.







The speaker thanked the organization, dean and convenor for giving him an opportunity to make friends and discuss something which is important to all of us in a forum like this. He further told that after several decades of work in academics and out of it now for nearly one and a half decades; not attending the conferences or did teaching or any other academic activities. But, it gives me an immense pleasure to be a part of a vibrant team like this and meet people to discuss on meaningful topic like the one chosen for this day.

He specially thanked all the participants who joined late in the afternoon. He wished them all a Happy new year. He further told that many of us have only bad memories about the year 2020 and told - remember only a bad year will give a good learning and emphasized that 2020 had given more learning in different dimensions of life than any other years before. With all the turmoil we entered in to a new year and we should take a resolution to make up for whatever was lost in the previous year and we move forward, not just move let's gallop forward;

with this say – he moved on to the ICH-GCP presentation. He said that it is vast topic; even a lecture for one week may not be sufficient to cover all the aspects of GCP. However, I will try to comprehensively present a birds eye view of this topic with major focus on the regulations for investigators in the clinical research. He then started his self-explanatory power point presentation – which are as follows. Then at the end of his presentation Q & A session and participants poll survey was carried out.

# Participants poll survey



# International Conference of Harmonization - Good Clinical Practice Guidelines E6 (R2)

**Dr. S. D. RAJENDRAN**

**DIRECTOR AND HEAD-OPERATIONS**

**SCITUS PHARMA SERVICES PRIVATE LIMITED, CHENNAI**

**E mail: [sd.rajendran@scitusbiolab.com](mailto:sd.rajendran@scitusbiolab.com)**

# What are GCPs?

GCPs are defined as standards for the design, conduct, performance, monitoring, auditing, recording, analysis and reporting of research studies

IT IS:

- More than rules on a piece of paper
- An attitude of credibility and excellence in research
- Mindset of dedication for quality
- A way to provide a standard for research
- A collection of practices to assure subject safety/protection of rights and data integrity

## Significance of GCP?

- ▶ Prevents research misconduct
- ▶ Protects the rights, safety and welfare of humans participating in research
- ▶ Assures quality, reliability and integrity of data collected
- ▶ Provides standards and guidance for the conduct of research

# HISTORY OF GCP

- **The Federal Food and Drugs Act, 1906**-The motive of this act was to prevent the manufacture, sale or distribution of adulterated or misbranded food or drugs.
- **Sulphanilamide Tragedy, 1937**- Elixir sulfanilamide was an improperly prepared sulfonamide antibiotic that caused mass poisoning in the United States in 1937. It caused the deaths of more than 100 people due to diethylene glycol (solvent).
- **The Nuremberg Code 1947**- established the need for informed consent and clearly designed scientific experiments for the benefit of human participants allowing them to withdraw from the experiment at any time.



# HISTORY OF GCP.....

- **Thalidomide Disaster of 1962-** Dr. William McBride found that the drug could be used for treating morning sickness in pregnant women. He started prescribing the drug to his pregnant patients and set up a trend. There were severe birth defects in the babies he delivered which was probably due to the intake of the so-called harmless compound.
- **Declaration of Helsinki-** The world medical association evolved “**Declaration of Helsinki**” in 1964. It formed the basic structure of the ethical principles that are fundamental to the ICH-GCP guidelines which we are in practice today. Current declaration was adopted in the 64th WMA General Assembly, Fortaleza, Brazil, October 2013.



# **International Conference on Harmonisation (ICH)**

**Guidelines for Good Clinical Practices**

## Objectives of ICH guidelines

- ▶ To provide a unified standard
- ▶ To harmonize clinical research of EU, US and Japan (major regions conducting clinical research)
- ▶ To facilitate mutual acceptance of clinical data
- ▶ Developed in accordance with existing standards in US, EU, Japan, Australia, Canada, Nordic Countries and WHO
- ▶ Adopted by several countries around the world
- ▶ India released its GCP guidelines in 2002

# Drug Development Pathway

## The Drug Research and Development Process

Discovery and origination of new compounds that become drug candidates



New compound efficacy and safety research

Confirmation of efficacy and safety in humans

Filing of new drug application with the Ministry of Health, Labour and Welfare (MHLW) and expert review

MHLW approval and listing in the National Health Insurance drug price list

Post-marketing check of safety and directions for use



# Who is Responsible for GCP Compliance?

- ▶ Clinical Investigators
- ▶ Sponsors
- ▶ Independent Ethics Committees/Institutional Review Boards/Contract Research Organizations
- ▶ Clinical Study Coordinators
- ▶ Clinical Research Associates
- ▶ Medical monitors
- ▶ Data entry personnel
- ▶ Subjects
- ▶ Other study team members

# How to be compliant?



## Must Adhere to:

- ▶ Regulations/Guidance:
  - ▶ Federal
  - ▶ State / Local
  - ▶ Institutional
  - ▶ Departmental
- ▶ *ICH GCP E6 (R2) guidance*
- ▶ IRB policies
- ▶ CRO/Sponsor polices/procedures



# ICH GCP E6 (R2)

An international quality standard that is provided by the International Conference on Harmonization

Universally recognized as a critical requirement to the conduct of research involving human subjects

**QUALITY** 

# ICH GCP E6 (R2)....

## ► Purpose:

- harmonize technical procedures and standards;
- improve quality and speed time to market
- First ICH-GCP guidelines was approved in July 1996
- In Jan 1997, various regulatory agencies, including US FDA endorsed the GCP Guidelines for clinical trials.



# 13 Principles of ICH GCPs

- Ethical conduct of clinical trials
- Benefits justify risks
- Rights, safety, and well-being of subjects prevail
- Non-clinical and clinical information supports the trial
- Compliance with a scientifically sound, detailed protocol
- IRB/IEC approval prior to initiation
- Medical care/decisions by qualified physician

# 13 Principles of ICH GCPs....

- Each individual is qualified (education, training, experience) to perform his/her assigned tasks
- Freely given informed consent from every subject prior to participation
- Accurate reporting, interpretation, and verification of clinical trial information
- Protects confidentiality of records
- IPs Conform to GMP's and used as per protocol
- QA Systems with procedures to ensure quality of every aspect of the trial.

# Topics covered by ICH GCP Guidelines

- ▶ Glossary
- ▶ Principles of ICH GCP
- ▶ Institutional Review Board/Independent Ethics Committee
- ▶ Investigator
- ▶ Sponsor
- ▶ Clinical Trial Protocol and Protocol Amendment(s)
- ▶ Investigator Brochure
- ▶ Essential Documents for the Conduct of a Clinical Trial

# ICH GCP E6 (R2) Sections

- Section 1 of ICH GCP Guideline -Glossary
- Section 2 of ICH GCP Guideline -Principles
- Section 3 of ICH GCP Guideline -IRB/IEC
- Section 4 of ICH GCP Guideline -Investigator
- Section 5 of ICH GCP Guideline -Sponsor
- Section 6 of ICH GCP Guideline -Clinical Trial Protocol/Amendments
- Section 7 of ICH GCP Guideline -Investigator's Brochure
- **Section 8 of ICH GCP Guideline -Essential Documents**

# ICH GCP Section 3

Institutional Ethics Committee/Institutional Review Board

# Responsibilities of Ethics Committee

- To protect the dignity, rights and well being of the potential research participants.
- To ensure that universal ethical values and international scientific standards are expressed in terms of local community values and customs.
- To assist in the development and the education of a research community responsive to local health care requirements

# IRB Reviews

- Behavioral vs. Biomedical
- Exempt vs. Expedited vs. Standard
- Non-human Subject and Non-research

# ICH GCP Section 4

**4.0-4.13**



# 4.1 Investigator's Qualifications and Agreements



Guideline	Description	How is this documented? Listings as applicable to the study
4.1.1	<p>The investigator should:</p> <ul style="list-style-type: none"> <li>• be qualified by education, training, and experience to assume responsibility for the proper conduct of the trial</li> <li>• should meet all the qualifications specified by the applicable regulatory requirements and should provide evidence of such qualifications through up to date CV requested by the sponsor/the IRB/IEC &amp; regulatory</li> </ul>	<p><b>Credentials:</b></p> <ul style="list-style-type: none"> <li>• CV/resume, current</li> <li>• Medical license</li> <li>• Certification</li> <li>• Training Log/documentation</li> <li>• Protocol Training documentation</li> <li>• GCP Training/CITI training</li> </ul>
4.1.2	<p>The investigator should be thoroughly familiar with the appropriate use of the investigational product(s), as described in the protocol, in the current Investigator's Brochure/SPC provided by the sponsor.</p>	<p><b>Training Log/Documentation:</b></p> <ul style="list-style-type: none"> <li>• Protocol</li> <li>• IB/drug insert/device manual/pharmacy manual</li> </ul>
4.1.3	<p>The investigator should be aware of, and should comply with, GCP and the applicable regulatory requirements.</p>	<p><b>Training Log/Documentation:</b></p> <ul style="list-style-type: none"> <li>• FDA Regulations/ICH GCP Guidelines</li> <li>• 1572</li> </ul>
4.1.4	<p>The investigator/institution should permit monitoring and auditing by the sponsor, and inspection by the appropriate regulatory authority.</p>	<p><b>Monitoring Log</b> <b>Signed CTA with Monitoring Plan</b></p>
4.1.5	<p>The investigator should maintain a list of appropriately qualified persons to whom the investigator has delegated significant trial-related duties.</p>	<p><b>Delegation of Authority Log</b> <b>CV/Resume for study staff, licenses/certifications (as applicable)</b></p>

## 4.2 Adequate Resources



Guideline	Description	How is this documented?
4.2.1	The investigator should be able to demonstrate (e.g., based on retrospective data) a potential for recruiting the required number of suitable subjects within the agreed recruitment period.	Study Feasibility Meeting/Questionnaire
4.2.2	The investigator should have sufficient time to properly conduct and complete the trial within the agreed trial period.	Study Feasibility Meeting/Questionnaire Documentation of ongoing studies
4.2.3	The investigator should have available an adequate number of qualified staff and adequate facilities for the foreseen duration of the trial to conduct the trial properly and safely.	Study Feasibility Meeting/Questionnaire
4.2.4	The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the investigational product(s), and their trial-related duties and functions.	Training Log
4.2.5	The investigator is responsible for supervising any individual or party to whom the investigator delegates trial-related duties and functions conducted at the trial site.	Training log Delegation of Authority Log Documentation of oversight
4.2.6	PI should ensure that any individual or party entrusted to perform trial related activities should be qualified to perform those trial related activities and should implement procedures to ensure the integrity of the trial-related activities performed and any data generated.	Credentials Certifications Documentation of oversight of results

## 4.3 Medical Care of Trial Subjects



Guideline	Description	How is this documented?
4.3.1	A qualified physician (or dentist, when appropriate), who is an investigator or a sub-investigator for the trial, should be responsible for all trial-related medical (or dental) decisions.	Delegation of Authority Inclusion/Exclusion Worksheets signed by PI PI oversight-review of labs, test results, progress notes
4.3.2	During and following a subject's participation in a trial, the investigator/institution should ensure that adequate medical care is provided to a subject for any AEs related to the trial. The investigator/institution should inform a subject when medical care is needed for intercurrent illness(es) of which the investigator becomes aware.	AE/SAE Log and Documentation Reports of diagnostic tests/labs, per protocol Progress notes Medical Records, if applicable
4.3.3	It is recommended that the investigator inform the subject's primary physician about the subject's participation in the trial if the subject has a primary physician and if the subject agrees to the primary physician being informed.	PCP letter, if subject agrees
4.3.4	Although a subject is not obliged to give his/her reason(s) for withdrawing prematurely from a trial, the investigator should make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights.	Contact subject via phone/mail, document accordingly

## 4.4 Communication with the IRB/IEC



Guidance	Description	How is this documented?
4.4.1	Before initiating a trial, the investigator/institution should have written and dated approval/favorable opinion from the IRB/IEC for the trial protocol, written informed consent form, consent form updates, subject recruitment procedures (e.g., advertisements), and any other written information to be provided to subjects.	Outcome Letter stating study is approved, approved consent forms, letter stating necessary protocol and forms are approved
4.4.2	As part of the investigator's/institution's written application to the IRB/IEC, the investigator/institution should provide the IRB/IEC with a current copy of the Investigator's Brochure. If the Investigator's Brochure is updated during the trial, the investigator/institution should supply a copy of the updated Investigator's Brochure to the IRB/IEC.	Application to IRB, including necessary documents needing approval
4.4.3	During the trial the investigator/institution should provide to the IRB/IEC all documents subject to review.	Amendments, progress reports, deviations, etc



## 4.5 Compliance with Protocol



Guidance	Description	How is this documented?
4.5.1	<p>The investigator/institution should conduct the trial in compliance with the protocol agreed to by the sponsor and, if required, by the regulatory authority(ies) and which was given approval/favorable opinion by the IRB/IEC. The investigator/institution and the sponsor should sign the protocol, or an alternative contract, to confirm agreement.</p>	<p>Signed 1572 Signed protocol signature page Clinical Trial Agreement (CTA) Source Documentation on all trial subjects, ALCOA-C Appointment calendars</p>
4.5.2	<p>The investigator should not implement any deviation from, or changes of the protocol without agreement by the sponsor and prior review and documented approval/favorable opinion from the IRB/IEC of an amendment, except where necessary to eliminate an immediate hazard(s) to trial subjects, or when the change(s) involves only logistical or administrative aspects of the trial (e.g., change in monitor(s), change of telephone number(s)).</p>	<p>Deviation Log Form 4, if applicable Appointment calendars</p>
4.5.3	<p>The investigator, or person designated by the investigator, should document and explain any deviation from the approved protocol.</p>	<p>Deviation Log</p>
4.5.4	<p>The investigator may implement a deviation from the protocol to eliminate an immediate hazard(s) to trial subjects without prior IRB/IEC approval/favorable opinion. As soon as possible, the implemented deviation, the reasons for it, and, if appropriate, the proposed protocol amendment(s) should be submitted: (a) to the IRB/IEC for review and approval/favorable opinion, (b) to the sponsor for agreement and, if required, (c) to the regulatory.</p>	<p>Deviation Log</p>

## 4.6 Investigational Product(s)



© Can Stock Photo

Guidance	Description	How is this documented?
4.6.1	Responsibility for investigational product(s) accountability at the trial site(s) rests with the investigator/institution.	IP Accountability Logs Drug Receipts/ distribution/ storage/ destruction/ return documentation
4.6.2	Where allowed/required, the investigator/institution may/should assign some or all of the investigator's/institution's duties for investigational product(s) accountability at the trial site(s) to an appropriate pharmacist or another appropriate individual who is under the supervision of the investigator/institution.	Delegation of Authority Training log
4.6.3	The investigator/institution and/or a pharmacist or other appropriate individual, who is designated by the investigator/institution, should maintain records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s). These records should include dates, quantities, batch/serial numbers, expiration dates (if applicable), and the unique code numbers assigned to the investigational product(s) and trial subjects. Investigators should maintain records that document adequately that the subjects were provided the doses specified by the protocol and reconcile all investigational product(s) received from the sponsor.	IP Accountability Logs Documentation of subject IP dispensing/instructions Drug Receipts/ distribution/ storage/ destruction/return documentation
4.6.4	The investigational product(s) should be stored as specified by the sponsor (see 5.13.2 and 5.14.3) and in accordance with applicable regulatory requirement(s).	Temperature Log IP Accountability Logs Subject instructions documentation
4.6.5	The investigator should ensure that the investigational product(s) are used only in accordance with the approved protocol.	IP Accountability Logs
4.6.6	The investigator, or a person designated by the investigator/institution, should explain the correct use of the investigational product(s) to each subject and should check, at intervals appropriate for the trial, that each subject is following the instructions properly.	Source Documents

# 4.7 Randomization Procedures and Unblinding



4.7

The investigator should follow the trial's randomization procedures, if any, and should ensure that the code is broken only in accordance with the protocol.

If the trial is blinded, the investigator should promptly document and explain to the sponsor any premature unblinding (e.g., accidental unblinding, unblinding due to a serious adverse event) of the investigational product(s).

Documentation outlining notifications of the need to unblind

Documentation of the steps taken in the unblinding process

Documentation of events taken once the unblinding had occurred

Documentation of subject events related to the need for unblinding

## 4.8 Informed Consent of Trial Subjects



Guidance	Description	How is this documented?
4.8.1	<p>In obtaining and documenting informed consent, the investigator should comply with the applicable regulatory requirement(s), and should adhere to GCP and to the ethical principles that have their origin in the Declaration of Helsinki. Prior to the beginning of the trial, the investigator should have the IRB/IEC's written approval/favorable opinion of the written informed consent form and any other written information to be provided to subjects.</p>	ICF Log/Version Log
4.8.2	<p>The written informed consent form and any other written information to be provided to subjects should be revised whenever important new information becomes available that may be relevant to the subject's consent. Any revised written informed consent form, and written information should receive the IRB/IEC's approval/favorable opinion in advance of use. The subject or the subject's legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the subject's willingness to continue participation in the trial. The communication of this information should be documented.</p>	Version, date on site source documents
4.8.3	<p>Neither the investigator, nor the trial staff, should coerce or unduly influence a subject to participate or to continue to participate in a trial.</p>	Site Source Documentation/ ICD



4.8.4	None of the oral and written information concerning the trial, including the written informed consent form, should contain any language that causes the subject or the subject's legally acceptable representative to waive or to appear to waive any legal rights, or that releases or appears to release the investigator, the institution, the sponsor, or their agents from liability for negligence.	Site Source Documentation/Informed Consent Documentation
4.8.5	The investigator, or a person designated by the investigator, should fully inform the subject or, if the subject is unable to provide informed consent, the subject's legally acceptable representative, of all pertinent aspects of the trial including the written information and the approval/ favorable opinion by the IRB/IEC.	Site Source Documentation/Informed Consent Documentation
4.8.6	The language used in the oral and written information about the trial, including the written informed consent form, should be as non-technical as practical and should be understandable to the subject or the subject's legally acceptable representative and the impartial witness, where applicable.	Site Source Documentation/Informed Consent Documentation

- ▶ If a subject is unable to read or if a legally acceptable representative is unable to read, an impartial witness should be present during the entire informed consent discussion.
- ▶ After the written informed consent form and any other written information to be provided to subjects, is read and explained to the subject or the subject's legally acceptable representative, and after the subject or the subject's legally acceptable representative has orally consented to the subject's participation in the trial and, if capable of doing so, has signed and personally dated the informed consent form, the witness should sign and personally date the consent form.
- ▶ By signing the consent form, the witness attests that the information in the consent form and any other written information was accurately explained to, and apparently understood by, the subject or the subject's legally acceptable representative, and that informed consent was freely given by the subject or the subject's legally acceptable representative.

- ▶ **Site Source Documentation/  
Informed Consent  
Documentation**

4.8.7	Before informed consent may be obtained, the investigator, or a person designated by the investigator, should provide the subject or the subject's legally acceptable representative ample time and opportunity to inquire about details of the trial and to decide whether or not to participate in the trial. All questions about the trial should be answered to the satisfaction of the subject or the subject's legally acceptable representative.	Site Source Documentation/Informed Consent Documentation
4.8.8	Prior to a subject's participation in the trial, the written informed consent form should be signed and personally dated by the subject or by the subject's legally acceptable representative, and by the person who conducted the informed consent discussion.	Site Source Documentation/Informed Consent Documentation

4.8.10 Both the informed consent discussion and the written informed consent form and Contains Nonbinding Recommendations 20 any other written information to be provided to subjects should include explanations of the following:

- (a) That the trial involves research.
- (b) The purpose of the trial.
- (c) The trial treatment(s) and the probability for random assignment to each treatment.
- (d) The trial procedures to be followed, including all invasive procedures.
- (e) The subject's responsibilities.
- (f) Those aspects of the trial that are experimental.
- (g) The reasonably foreseeable risks or inconveniences to the subject and, when applicable, to an embryo, fetus, or nursing infant.
- (h) The reasonably expected benefits. When there is no intended clinical benefit to the subject, the subject should be made aware of this.
- (i) The alternative procedure(s) or course(s) of treatment that may be available to the subject, and their important potential benefits and risks.
- (j) The compensation and/or treatment available to the subject in the event of trial related injury.
- (k) The anticipated prorated payment, if any, to the subject for participating in the trial.
- (l) The anticipated expenses, if any, to the subject for participating in the trial.

(m) That the subject's participation in the trial is voluntary and that the subject may refuse to participate or withdraw from the trial, at any time, without penalty or loss of benefits to which the subject is otherwise entitled.

(n) That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority(ies) will be granted direct access to the subject's original medical records for verification of clinical trial procedures and/or data, without violating the confidentiality of the subject, to the extent permitted by the applicable laws and regulations and that, by signing a written informed consent form, the subject or the subject's legally acceptable representative is authorizing such access.

(o) That records identifying the subject will be kept confidential and, to the extent permitted by the applicable laws and/or regulations, will not be made publicly available. If the results of the trial are published, the subject's identity will remain confidential.

(p) That the subject or the subject's legally acceptable representative will be informed in a timely manner if information becomes available that may be relevant to the subject's willingness to continue participation in the trial.

(q) The person(s) to contact for further information regarding the trial and the rights of trial subjects, and whom to contact in the event of trial-related injury.

(r) The foreseeable circumstances and/or reasons under which the subject's participation in the trial may be terminated.

(s) The expected duration of the subject's participation in the trial. Contains Nonbinding Recommendations 21 (t) The approximate number of subjects involved in the trial

4.8.11	<p>Prior to participation in the trial, the subject or the subject's legally acceptable representative should receive a copy of the signed and dated written informed consent form and any other written information provided to the subjects. During a subject's participation in the trial, the subject or the subject's legally acceptable representative should receive a copy of the signed and dated consent form updates and a copy of any amendments to the written information provided to subjects.</p>	Site Source Documentation/Informed Consent Documentation
4.8.12	<p>When a clinical trial (therapeutic or non-therapeutic) includes subjects who can only be enrolled in the trial with the consent of the subject's legally acceptable representative (e.g., minors, or patients with severe dementia), the subject should be informed about the trial to the extent compatible with the subject's understanding and, if capable, the subject should sign and personally date the written informed consent.</p>	Site Source Documentation/Informed Consent Documentation
4.8.13	<p>Except as described in 4.8.14, a non-therapeutic trial (i.e. a trial in which there is no anticipated direct clinical benefit to the subject), should be conducted in subjects who personally give consent and who sign and date the written informed consent form.</p>	Site Source Documentation/Informed Consent Documentation

4.8.14

Non-therapeutic trials may be conducted in subjects with consent of a legally acceptable representative provided the following conditions are fulfilled:

- (a) The objectives of the trial cannot be met by means of a trial in subjects who can give informed consent personally.
- (b) The foreseeable risks to the subjects are low.
- (c) The negative impact on the subject's well-being is minimized and low.
- (d) The trial is not prohibited by law.
- (e) The approval/favorable opinion of the IRB/IEC is expressly sought on the inclusion of such subjects, and the written approval/ favorable opinion covers this aspect.

Such trials, unless an exception is justified, should be conducted in patients having a disease or condition for which the investigational product is intended. Subjects in these trials should be particularly closely monitored and should be withdrawn if they appear to be unduly distressed.

Site Source  
Documentation/  
Informed  
Consent  
Documentation

4.8.15

In emergency situations, when prior consent of the subject is not possible, the consent of the subject's legally acceptable representative, if present, should be requested.


When prior consent of the subject is not possible, and the subject's legally acceptable representative is not available, enrolment of the subject should require measures described in the protocol and/or elsewhere, with documented approval/favorable opinion by the IRB/IEC, to protect the rights, safety and well-being of the subject and to ensure compliance with applicable regulatory requirements.

The subject or the subject's legally acceptable representative should be informed about the trial as soon as possible and consent to continue and other consent as appropriate (see 4.8.10) should be requested.

Site Source  
Documentation/Informed  
Consent  
Documentation



# 4.9 Records and Reports



4.9.1	The investigator should ensure the accuracy, completeness, legibility, and timeliness of the data reported to the sponsor in the CRFs and in all required reports.	Source Documentation on all subjects, ALCOA-C CRF documentation
4.9.2	Data reported on the CRF, that are derived from source documents, should be consistent with the source documents or the discrepancies should be explained.	Source Documentation on all subjects, ALCOA-C Notes to File Progress notes

4.9.3

Any change or correction to a CRF should be dated, initialed, and explained (if necessary) and should not obscure the original entry (i.e. an audit trail should be maintained); this applies to both written and electronic changes or corrections Sponsors should provide guidance to investigators and/or the investigators' designated representatives on making such corrections. Sponsors should have written procedures to assure that changes or corrections in CRFs made by sponsor's designated representatives are documented, are necessary, and are endorsed by the investigator. The investigator should retain records of the changes and corrections.

Source Documentation on all subjects, ALCOA-C  
Notes to File  
Progress notes

4.9.4

The investigator/institution should maintain the trial documents as specified in Essential Documents for the Conduct of a Clinical Trial and as required by the applicable regulatory requirement(s). The investigator/institution should take measures to prevent accidental or premature destruction of these documents.

Regulatory Binder, up to date  
with all essential documents

4.9.5 Essential documents should be retained until at least 2-years after the last approval of a marketing application in an ICH region and until **there are no pending** or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period, however, if required by the applicable regulatory requirements or by an agreement with the sponsor. It is the responsibility of the sponsor to inform the investigator/institution as to when these documents no longer need to be retained (see section 5.5.12).

4.9.6 The financial aspects of the trial should be documented in an agreement between the sponsor and the investigator/institution.

4.9.7 Upon request of the monitor, auditor, IRB/IEC, or regulatory authority, the investigator/institution should make available for direct access all requested trial related records.

## 4.10 Progress Reports



## 4.10 Progress Reports

4.10.1 The investigator should submit **written summaries of the trial's status to the IRB/IEC annually**, or more frequently, if requested by the IRB/IEC.

4.10.2 The investigator should promptly provide written reports to the sponsor, the IRB/IEC (see section 3.3.8) and, where applicable, the institution on any changes significantly affecting the conduct of the trial, and/or increasing the risk to subjects.



## 4.11 Safety Reporting



4.11.1	<p>All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports. The immediate and follow-up reports should be as detailed as possible.</p> <p>The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.</p>	SAE/AE Logs and Documentation Concomitant medication logs Diaries, if applicable Progress notes
4.11.2	<p>Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.</p>	SAE/AE Logs and Documentation
4.11.3	<p>For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).</p>	SAE/AE Logs and Documentation



## 4.12 Premature Termination or Suspension of a Trial



4.12.1	If the investigator terminates or suspends a trial without prior agreement of the sponsor, the investigator should inform the institution where applicable, and the investigator/institution should promptly inform the sponsor and the IRB/IEC, and should provide the sponsor and the IRB/IEC a detailed written explanation of the termination or suspension.	IRB/institution/IRB/subject notification
4.12.2	If the sponsor terminates or suspends a trial (see 5.21), the investigator should promptly inform the institution where applicable and the investigator/institution should promptly inform the IRB/IEC and provide the IRB/IEC a detailed written explanation of the termination or suspension.	IRB/institution/subject notification
4.12.3	If the IRB/IEC terminates or suspends its approval/favorable opinion of a trial (see 3.1.2 and 3.3.9), the investigator should inform the institution where applicable and the investigator/institution should promptly notify the sponsor and provide the sponsor with a detailed written explanation of the termination or suspension.	Notify the institution/subjects/sponsor

## 4.13 Final Report(s) by Investigator



4.13

Upon completion of the trial, the investigator, where applicable, should inform the institution; the investigator/institution should provide the IRB/IEC with a summary of the trial's outcome, and the regulatory authority(ies) with any reports required.

Close-out form submitted to the IRB  
Storage of the essential Documents for the appropriate time outlined in the regulations/guidance/CTA  
Notify the sponsor/IRB (if applicable) of a change in storage location as necessary

# Section 5: Sponsor



# Sponsor Responsibilities

- ▶ In the conduct of a **clinical trial**, a **sponsor** is an individual, institution, company or organization (for example, a contract **research organization**) that takes the **responsibility** to initiate, manage or finance the **clinical trial**, but does not actually conduct the investigation.
- ▶ The sponsor is responsible for implementing and maintaining quality assurance and quality control systems with written SOPs to ensure that **trials** are conducted and data are generated, documented (recorded), and reported in compliance with the protocol, **GCP**, and the applicable regulatory requirements.

# ICH GCP Section 8



# 8. ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

- The sponsor and investigator/institution should maintain a record of the location(s) of their respective essential documents including source documents.
- The storage system used during the trial and for archiving (irrespective of the type of media used) should provide for document identification, version history, search, and retrieval.
- Essential documents for the trial should be supplemented or may be reduced where justified (in advance of trial initiation), based on the importance and relevance of the specific documents to the trial.
- The sponsor should ensure that the investigator has control of and continuous access to the CRF data reported to the sponsor.
- The sponsor should not have exclusive control of those data. When a copy is used to replace an original document (e.g., source documents, CRF), the copy should fulfill the requirements for certified copies.
- The investigator/institution should have control of all essential documents and records generated by the investigator/institution before, during, and after the trial.



